Design and Synthesis of 4-Azaindoles as Inhibitors of p38 MAP Kinase

Journal of Medicinal Chemistry

Volumn 46, Issue 22, 2003, Pages 4702-4713

  Trejo, Alejandra ^a   Arzeno, Humberto ^a   Browner, Michelle ^a   Chanda, Sushmita ^a   Cheng, Soan ^a   Comer, Daniel D ^a,b   Dalrymple, Stacie A ^a   Dunten, Pete ^a   Lafargue, JoAnn ^a   Lovejoy, Brett ^a   Freire Moar, Jose ^a   Lim, Julie ^a   McIntosh, Joel ^a   Miller, Jennifer ^a,d   Papp, Eva ^a   Reuter, Deborah ^a   Roberts, Rick ^a   Sanpablo, Florentino ^a   Saunders, John ^a,c   Song, Kyung ^a   Villasenor, Armando ^a   Warren, Stephen D ^a,e   Welch, Mary ^a   Weller, Paul ^a   Whiteley, Phyllis E ^a   Zeng, Lu ^a   Goldstein, David M ^a   more..

^a ROCHE BIOSCIENCE   (United States)

^b Neurogenetics Inc   (United States)

^c NEUROCRINE BIOSCIENCES INC   (United States)

^d Signature Bioscience Inc   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 [3 (4 FLUOROPHENYL) 1H PYRROLO[3,2 B]PYRIDIN 2 YL]PYRIDIN 2 YLAMINO]PROPAN 2 OL; HETEROCYCLIC COMPOUND; INDOLE DERIVATIVE; INTERLEUKIN 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNE DISEASE; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; NONHUMAN; REACTION ANALYSIS; X RAY CRYSTALLOGRAPHY;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CELL LINE; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROGEN BONDING; INDOLES; INJECTIONS, INTRAVENOUS; MITOGEN-ACTIVATED PROTEIN KINASE 14; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN ISOFORMS; PYRIDINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0142060917     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0301787     Document Type: Article

References (49)

1. (a) Adams, J. L.; Badger, A. M.; Kumar, S.; Lee, J. C. p38 MAP kinase: molecular target for the inhibition of pro-inflainmatory cytokines. Prog. Med. Chem. 2001, 38, 1-60.
2. (b) Lee, J. C.; Kumar, S.; Griswold, D. E.; Underwood, D. C.; Votta, B. J.; Adams, J. L. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 2000, 47, 185-201.
3. (a) Schett, G.; Tohidast-Akrad, M.; Smolen, J. S.; Schmid, B. J.; Steiner, C.; Bitzan, P.; Zenz, P.; Redlich, K.; Xu, Q.; Steiner, G. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum. 2000, 43, 2501-2512.
4. (b) Foster, M. L.; Halley, F.; Souness, J. E. Potential of p38 inhibitors in the treatment of rheumatoid arthritis. Drug News Perspect. 2000, 13, 488-497.
5. (a) Jones R E.; Moreland, L. W. Tumor necrosis factor inhibitors for rheumatoid arthritis. Bull. Rheum. Dis. 1999, 48, 1-4.
6. (b) Tumor Necrosis Factor Antagonists as Potential Treatments in Rheumatoid Arthritis. A CME Satellite Symposium at the American College of Rheumatology Annual Meeting, held 12 November 1998, in San Diego, California. J. Rheum. Suppl. 1999, 57.
7. (c) Hommes, D.; van Den Blink, B.; Plasse, T.; Bartelsman J.; Cuiping, X.; Macpherson, B.; Tytgat, G.; Peppelenbosch, M.; Van Deventer, S. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002, 122, 7-14.
8. (a) Lee, J. C.; Kumar, S.; Griswold, D. E.; Underwood, D. C.; Votta, B. J.; Adams, J. L. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 2000, 47, 185-201.
9. (b) Boehm, J. C.; Adams, J. L. New inhibitors of p38 kinase. Expert Opin. Ther. Pat. 2000, 10, 25-37.
10. (c) Mclay, L. M.; Halley, F.; Souness, J. E.; McKenna, J.; Benning, V.; Birrell, M.; Burton, B.; Belvisi, M.; Collis, A.; Constan, A.; Foster, M.; Hele, D.; Jayyosi, Z.; Kelley, M.; Maslen, C.; Miller, G.; Ouldelhkim, M. C.; Page, K.; Phipps, S.; Pollock, K.; Porter, B.; Ratcliffe, A. J.; Redford, E. J.; Webber, S.; Slater, B.; Thybaud, V.; Wilsher, N. The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral antiarthritic efficacy. Bioorg. Med. Chem. 2001, 9, 537-54.
11. (d) Wadsworth, S. A.; Cavender, D. E.; Beers, S. A.; Lalan, P.; Schafer, P. H.; Malloy, E. A.; Wu, W.; Fahmy, B.; Olini, G. C.; Davis, J. E.; Pellegrino-Gensey, J. L.; Wachter, M. P.; Siekierka, J. J. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J. Pharm. Exp. Ther. 1999, 291, 680-687.
12. (e) Dumas, J.; Sibley, R.; Riedl, B.; Monahan, M. K.; Lee, W.; Lowinger, T. B.; Redman, A. M.; Johnson, J. S.; Kingery-Wood, J.; Scott, W. J.; Smith, R. A.; Bobko, M.; Schoenleber, R.; Ranges, G. E.; Housley, T. J.; Bhargava, A.; Wilhelm, S. M.; Shrikhande, A Discovery of a new class of p38 kinase inhibitors. Bioorg. Med. Chem. Lett. 2000, 10, 2047-2050.
13. (f) Feldmann, M.; Brennan, F. M.; Maini, R. N. Potential of p38 inhibitors in the treatment of rheumatoid arthritis. Annu. Rev. Immunol. 1996, 14, 397-440.
14. (a) Boehm, J. C.; Smietana, J. M.; Sorenson, M. E.; Garigipati, R. S.; Gallagher, T. F.; Sheldrake, P. L.; Bradbeer, J.; Badger, A. M.; Laydon, J. T.; et al. 1-Substituted 4-Aryl-5-pyridinylimidazoles: A New Class of Cytokine Suppressive Drugs with Low 5-Lipoxygenase and Cyclooxygenase Inhibitory Potency. J. Med. Chem. 1996, 39, 3929-3937.
15. (b) Gallagher, T. F.; Seibel, G. L.; Kassis, S.; Laydon, J. T.; Blumenthal, M. J.; Lee, J C.; Lee, D.; Boehm, J., C.; Fier-Thompson, S. M.; Abt, J. W.; Soreson, M. E.; Smietana, J. M.; Hall, R. F.; Garigipati, R. S; Bender, P. E; Erhard, K. F; Krog, A. J.; Hofmann, G. A.; Sheldrake, P. L.; McDonnell, P. C.; Kumar, S.; Young, P. R.; Adams, J. L. Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase. Bioorg. Med. Chem. 1997, 5, 49-64.
16. (c). Liverton, N. J.; Butcher, J. W.; Claiborne, C. F.; Claremon, D. A.; Libby, B. E.; Nguyen, K. T.; Pitzenberger, S. M.; Selnick, H. G.; Smith, G. R.; Tebben, A.; Vacca, J. P.; Varga, S. L.; Agarwal, L.; Dancheck, K.; Forsyth, A. J.; Fletcher, D. S.; Frantz, B.; Hanlon, W. A.; Harper, C.I F.; Hofsess, S. J.; Kostura, M.; Lin, J.; Luell, S.; O'Neil], E. A.; Orevillo, C. J.; Pang, M.t; Parsons, J.; Rolando, A.; Sahly, Yousif; V., Denise M.; O'Keefe, S. J. Design and Synthesis of Potent, Selective, and Orally Bioavailable Tetrasubstituted Imidazole Inhibitors of p38 Mitogen-Activated Protein Kinase. J. Med. Chem. 1999, 42, 2180-2190.
17. (d) Perregaux, D. G.; Dean, D.; Cronan, M.; Connelly, P.,; Gabel, C. A Inhibition of interleukin-1 beta production by SKF86002: evidence of two sites of in vitro activity and of a time and system dependence. Mol. Pharm. 1995, 48, 433-42.
18. (e) Pier, C.; Pargellis, C.; Regan, J. The Non-Diaryl Heterocycle Classes of p38 MAP Kinase Inhibitors. Curr. Top. Med. Chem. 2002, 2, 1021-1035.
19. (e) Jackson, P. F.; Bullington, J. L. Pyridinylimidazole Based p38 MAP Kinase Inhibitors. Curr. Top. Med. Chem. 2002, 2, 1011-1020.
20. Jackson, P. F.; Bullington, J. L. Pyridinylimidazole Based p38 MAP Kinase Inhibitors. Curr. Top. Med. Chem. 2002, 2, 1011-1020.
21. Tong, L.; Pav, S.; White, D.; Rogers, S.; Crane, K.; Cywin, C. A. Highly Specific Inhibitor of Human p38 MAP Kinase Binds in the ATP Pocket. Nat. Struct. Biol. 1997, 4, 311-316. Young, P. R.; McLaughlin, M.; Kumar, S.; Kassis, S.; Doyle, M. L.; McNulty, D.; Gallagher, T. F.; Fisher, S.; McDonnell, P. C.; Carr, S. A.; Huddleston, M. J.; Seibel, G.; Porter, T. G.; Livi, G. P.; Adams, J. L. ; Lee, J. C. Pyridinyl Imidazole Inhibitors of p38 Mitogen-Activated Protein Kinase Bind in the ATP Site. J. Biol. Chem. 1997, 272, 12116-12121.
22. Tong, L.; Pav, S.; White, D.; Rogers, S.; Crane, K.; Cywin, C. A. Highly Specific Inhibitor of Human p38 MAP Kinase Binds in the ATP Pocket. Nat. Struct. Biol. 1997, 4, 311-316. Young, P. R.; McLaughlin, M.; Kumar, S.; Kassis, S.; Doyle, M. L.; McNulty, D.; Gallagher, T. F.; Fisher, S.; McDonnell, P. C.; Carr, S. A.; Huddleston, M. J.; Seibel, G.; Porter, T. G.; Livi, G. P.; Adams, J. L. ; Lee, J. C. Pyridinyl Imidazole Inhibitors of p38 Mitogen-Activated Protein Kinase Bind in the ATP Site. J. Biol. Chem. 1997, 272, 12116-12121.
23. Boehm, J. C.; Adams, J. L. New Inhibitors of p38 Kinase. Expert Opin. Ther. Pat. 2000, 10, 25-37.
24. Lee, J. C.; Kassis, S.; Kumar, S.; Badger, A.; Adams, J. L. P38 Mitogen-Activated Protein Kinase Inhibitor- Mechanisms and Therapeutic Potentials. Pharmacol. Ther. 1999, 82, 389-397.
25. Wang, Z.; Canagarajah, B. J.; Boehm, J. C.; Kassisa, S.; Cobb, M. H.; Young, P.IR.; Abdel-Meguid, S.; Adams, J. L.; Goldsmith, E. J. Structural Basis of Inhibitor Selectivity in MAP Kinases. Structure 1998, 6, 1117-1128.
26. (a) Shewchuk, L.; Hassell, A.; Wisely, B.; Rocque, W.; Holmes, W.; Veal, J.; Kuyper, L. F. Binding Mode of the 4-Anilinoquinazoline Class of Protein Kinase Inhibitor: X-ray Crystallographic Studies of 4-Anilinoquinazoline Bound to Cyclin-Dependent Kinase 2 and p38 Kinase. J. Med. Chem. 2000, 43, 133-138.
27. (b) Mettey, Y.; Gompel, M.; Thomas, V.; Garnier, M.; Leost, M.; Ceballos-Picot, I.; Noble, M.; Endicott, J.; Vierfont, J.; Meijer, L. Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study, Crystal Structure in Complex with CDK2, Enzyme Selectivity, and Cellular Effects. J. Med. Chem. 2003, 46, 222-236.
28. 7. Chen, C.; Lieberman, D. R.; Larsen, R. D.; Verhoeven, T. R.; Reider, P.1 J. Syntheses of Indoles via a Palladium-Catalyzed Annulation between Iodoanilines and Ketones. J. Org. Chem. 1997, 62, 2676-2677.
29. Turner, J. A. Regiospecific Electrophilic Substitution of Aminopyridines: Ortho Lithiation of 2-, 3-, and 4-(Pivaloylamino) pyridines. J. Org. Chem. 1983, 48, 3401-8.
30. (a) Fustner, A.; Hupperts, A.; Ptock, A.; Janssen, E. "Site Selective" Formation of Low-Valent Titanium Reagents: An "Instant" Procedure for the Reductive Coupling of Oxo Amides to Indoles. J. Org. Chem. 1994, 59, 5215-29.
31. (b) Fuerstner, A.; Ernst, A.; Krause, H.; Ptock, A. Low-valent titanium induced indole formation: syntheses of secofascaplysin, indolopyridocoline and an endothelin-receptor-antagonist. Tetrahedron 1996, 52, 7329-7344.
32. Robinson B., Eds. The Fisher Indole Synthesis; John Wiley & Sons: Chichester, 1982; pp 48-59.
33. Chan, S.; et al., unpublished results (manuscript in preparation).
34. (a) Mann, G.; Hartwig, J. F.; Driver, M. S.; Fernández-Rivas, C. J. Am. Chem. Soc. 1998, 120, 827-828.
35. (b) Wagaw, S.; Yang, B. H.; Buchwald, S. L. A palladium-catalysed Strategy for the preparation of indoles. A novel entry into the fisher indole synthesis. J. Am. Chem. Soc. 1998, 120, 6621-6622.
36. Barlin, G. B.; Davies, L. P.; Ireland, S. J.; Ngu, M. M. L. Imidazo-[1,2-b] pyridazines. VI. Synthesis and central nervous system activities of some 6-(alkoxy-and methylthio-phenoxy and methoxy-2-phenyl (substituted phenyl and pyridinyl) imidazo [1,2- b] pyridazines. Aust. J. Chem. 1989, 42, 1735-1748.
37. 1 Selective adenosine receptor antagonists. J. Med. Chem. 1990, 33, 2822-2828.
38. Greene, T. W.; Wuts, P. G. M., Eds. Protective Groups in Organic Synthesis; John Wiley & Sons: New York, 1991; pp 77-83.
39. Shiotani, S.; Morita, H. Furopyridines III a New Synthesis of Furo[3,2-b]pyridine. J. Heterocycl. Chem. 1986, 23, 665-668.
40. Tanaka, S. Coumarones from o-hydroxy aldehydes and bromomalonic ester. J. Am. Chem. Soc. 1951, 73, 872.
41. Solberg, J.; Undheim, K. Regiochemistry in Pd-catalysed organotin reactions with halopyrimidines. Acta Chem. Scand. 1989, 43, 62-68.
42. Stille, J. K. Angew. Chem., Int. Ed. Engl. 1986, 25, 508.
43. Coperet, C.; Adolfsson, H.; Chiang, J. P.; Yudin, A. K.; Sharpless, K. B. A simple and efficient method for the preparation of pyridine-N-oxides II. Tetrahedron Lett. 1998, 39, 761-764.
44. Sheldrake, P. W. The Anion of 4-Dimethoxymethylpyridine. A convenient synthesis of some 4-pyridyl ketones. Synth. Commun. 1993, 23, 1967-1971.
45. 50's of 6.5 nM and 150 nM, respectively. P38 γ and δ are not inhibited at concentrations up to 100 μM.
46. Brunger A. T. Xplor: Version 3.1; Yale Press: New Haven, 1987.
47. (b) Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-liklihood method. Acta Crystallogr. 1997, D53, 240-255.
48. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne P. E. The Protein Data Bank. Nucleic Acid Res. 2000, 28, 235-242.
49. Reimund, J. M., et al. Gut 1996, 39, 684-689.